JP6893873B2 - 新規の再生治療剤としてのｃａｍｋｋ１ - Google Patents

新規の再生治療剤としてのｃａｍｋｋ１ Download PDF

Info

Publication number
JP6893873B2
JP6893873B2 JP2017530094A JP2017530094A JP6893873B2 JP 6893873 B2 JP6893873 B2 JP 6893873B2 JP 2017530094 A JP2017530094 A JP 2017530094A JP 2017530094 A JP2017530094 A JP 2017530094A JP 6893873 B2 JP6893873 B2 JP 6893873B2
Authority
JP
Japan
Prior art keywords
camkk1
tissue
organ
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017530094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502838A (ja
JP2018502838A5 (https=
Inventor
ペン、マーク、エス．
キードロウスキー、マシュー
マヨルガ、マリッツァ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeast Ohio Medical University
Summa Health Systems LLC
Original Assignee
Northeast Ohio Medical University
Summa Health Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Ohio Medical University, Summa Health Systems LLC filed Critical Northeast Ohio Medical University
Publication of JP2018502838A publication Critical patent/JP2018502838A/ja
Publication of JP2018502838A5 publication Critical patent/JP2018502838A5/ja
Priority to JP2021032502A priority Critical patent/JP2021098717A/ja
Application granted granted Critical
Publication of JP6893873B2 publication Critical patent/JP6893873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
JP2017530094A 2014-12-01 2015-12-01 新規の再生治療剤としてのｃａｍｋｋ１ Active JP6893873B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021032502A JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086026P 2014-12-01 2014-12-01
US62/086,026 2014-12-01
PCT/US2015/063118 WO2016089826A1 (en) 2014-12-01 2015-12-01 Camkk1 as a novel regenerative therapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021032502A Division JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Publications (3)

Publication Number Publication Date
JP2018502838A JP2018502838A (ja) 2018-02-01
JP2018502838A5 JP2018502838A5 (https=) 2019-01-17
JP6893873B2 true JP6893873B2 (ja) 2021-06-23

Family

ID=56092307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017530094A Active JP6893873B2 (ja) 2014-12-01 2015-12-01 新規の再生治療剤としてのｃａｍｋｋ１
JP2021032502A Pending JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021032502A Pending JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Country Status (12)

Country Link
US (2) US11273208B2 (https=)
EP (2) EP3940068A1 (https=)
JP (2) JP6893873B2 (https=)
KR (3) KR102610068B1 (https=)
AU (1) AU2015355188B2 (https=)
CA (1) CA3007055C (https=)
CL (1) CL2017001390A1 (https=)
CR (1) CR20170301A (https=)
IL (2) IL252612B (https=)
RU (1) RU2017122817A (https=)
UA (1) UA124450C2 (https=)
WO (1) WO2016089826A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124450C2 (uk) * 2014-12-01 2021-09-22 Самма Хелт Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта
EP3781182A4 (en) 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
EP1372678A2 (en) 2001-03-09 2004-01-02 Board of Regents, The University of Texas System Vectors, compositions and methods for treating a vascular disorder
WO2006124013A2 (en) 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
WO2006015127A2 (en) * 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
KR20070085288A (ko) 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
US20090246179A1 (en) 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
UA124450C2 (uk) * 2014-12-01 2021-09-22 Самма Хелт Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта
JP6797803B2 (ja) 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法

Also Published As

Publication number Publication date
KR20210010662A (ko) 2021-01-27
UA124450C2 (uk) 2021-09-22
AU2015355188B2 (en) 2021-08-26
AU2015355188A1 (en) 2017-07-20
KR102610068B1 (ko) 2023-12-06
US20170340712A1 (en) 2017-11-30
IL284408B (en) 2022-06-01
CA3007055C (en) 2023-08-01
JP2021098717A (ja) 2021-07-01
EP3940068A1 (en) 2022-01-19
JP2018502838A (ja) 2018-02-01
IL252612B (en) 2021-07-29
RU2017122817A3 (https=) 2019-06-11
EP3227441A1 (en) 2017-10-11
IL284408A (en) 2021-07-29
WO2016089826A1 (en) 2016-06-09
EP3227441A4 (en) 2018-08-15
CR20170301A (es) 2018-02-01
US20220233653A1 (en) 2022-07-28
IL252612A0 (en) 2017-07-31
KR102460983B1 (ko) 2022-10-31
RU2017122817A (ru) 2019-01-10
CA3007055A1 (en) 2016-06-09
BR112017011490A2 (pt) 2018-02-27
EP3227441B1 (en) 2021-06-30
KR20170088988A (ko) 2017-08-02
KR102236843B1 (ko) 2021-04-07
US11273208B2 (en) 2022-03-15
KR20220151004A (ko) 2022-11-11
CL2017001390A1 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
US20210030851A1 (en) Compositions and methods for treating spinal muscular atrophy
Korpela et al. Gene therapy for ischaemic heart disease and heart failure
CN113166777B (zh) 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
EP3924048A1 (en) Myc, cyclin t1 and/or cdk9 for use in the treatment of degenerative heart and cns disorders
US20180271942A1 (en) Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
WO2017151717A1 (en) Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
JP2021098717A (ja) 新規の再生治療剤としてのｃａｍｋｋ１
CN110167564B (zh) 调节tjp1表达以调节心脏细胞的再生
CN119013405A (zh) 包含utr的核酸构建体及其应用
BR112017011490B1 (pt) Uso de plasmídeo ou vetor viral, compreendendo um ácido nucleico que codifica camkk1
US20240301355A1 (en) Methods of inducing cardiac cell proliferation and inducing heart regeneration
EP2586865B1 (en) Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
JP7588414B2 (ja) 心房細動の遺伝子療法による治療
WO2007013719A1 (en) Recombinant adeno-associated virus comprising vegfr truncated soluble cdna and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same
CN116761812A (zh) Neurod1和dlx2载体
KR20250057176A (ko) Arid4b 유전자 발현을 통한 신경세포로의 직접교차분화 유도 방법
JP2023530422A (ja) 転写因子ｅｔｖ２遺伝子を用いた直接インビボリプログラミングによる内皮細胞および血管の形成
CN113956345A (zh) Angpt4蛋白及其编码基因在调控心脏损伤后的修复与再生能力中的应用
CN117597151A (zh) 强直性肌肉营养不良1型治疗药
WO2007026973A1 (en) Recombinant adeno-associated virus containing vegfr truncated cdna and gene therapeutic agent for cancer comprising the same
CA2834729A1 (en) A skeletal muscle-specific enhancer

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210602

R150 Certificate of patent or registration of utility model

Ref document number: 6893873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250